Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: Preliminary results

Rheumatology International

Volumn 27, Issue 7, 2007, Pages 649-654

  Caramaschi, Paola ^a,b   Ruzzenente, Orazio ^a   Pieropan, Sara ^a   Volpe, Alessandro ^a   Carletto, Antonio ^a   Bambara, Lisa Maria ^a   Biasi, Domenico ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Medicina Interna C   (Italy)

Author keywords

Ankylosing spondylitis; Antinuclear antibodies; Infliximab; Multiplexed fluorescent microsphere immunoassay; Rheumatoid arthritis

Indexed keywords

ANTINUCLEAR ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; INFLIXIMAB; LA ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT MICROSPHERE IMMUNOASSAY; FLUOROIMMUNOASSAY; HEP 2 CELL; HUMAN; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MALE; MICROSPHERES; MIDDLE AGED; PILOT PROJECTS; SPONDYLITIS, ANKYLOSING;

EID: 34247265971     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-006-0271-8     Document Type: Article

References (24)

1. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys E, De Keyser F (2005) Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main anti-nuclear reactivity. Biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 52:2192-2201
2. Forger F, Matthias T, Oppermann M, Becker H, Helmke K (2004) Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus 13:36-44
3. Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N (2004) Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 6:R535-R543
4. Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, Volpe A, Pacor ML, Bambara LM (2006) Anti-TNF α therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int 26:209-214
5. Atzeni F, Sarzi-Puttini P, Dell'Acqua D, de Portu S, Cecchini G, Cruini C, Carrabba M, Meroni PL (2005) Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 8:R3
6. De Bandt M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C, Boucquillard E, Siame JL, Mariette X, Club Rhumatismes et Inflammation (2005) Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7:R545-R551
7. Charles PJ, Smeenk RJT, De Jong J, Feldmann M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α. Arthritis Rheum 43:2383-2390
8. Bickerstaff MC, Botto M, Hutchinson WL, Herbert J, Tennent GA, Bybe A, Mitchell DA, Cook HT, Butler PJ, Walport MJ, Pepys MB (1999) Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 5:694-697
9. Gershow D, Kim S, Brot N, Elkon KB (2000) C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 192:1353-1364
10. Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD (2001) In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 167:6821-6826
11. Von Muhlen CA, Tan EM (1995) Antibodies in diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 24:232-258
12. Martins TB, Burlingame R, von Muhlen CA, Jaskowski TD, Litwin CM, Hill HR (2004) Evaluation of multiplexed fluorescent microsphere immunoassay for detection of autoantibodies to nuclear antigens. Clin Diagn Lab Immunol 11:1054-1059
13. Pang S, Smith J, Onley D, Reeve J, Walker M, Foy CA (2005) Comparability study of the emerging protein array platforms with established ELISA procedures. J Immunol Methods 302:1-12
14. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, Jones JA, Harley JB (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526-1533
15. Favalli EG, Sinigaglia L, Varenna M, Arnoldi C (2000) Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 11:753-755
16. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563
17. Maini RN, St Clair EW, Breedveld FC, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 354:1932-1939
18. De Bandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O (2003) Anti-TNF-alpha-induced systemic lupus erythematosus. Clin Rheumatol 22:56-61
19. Klapman JB, Ene-Stroescu D, Becker MA, Hananuer SB (2003) A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 9:176-178
20. Mohan AK Edwards ET, Coté TR, Siegel JN, Braun MM (2002) Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 360:646
21. Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P (2002) Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn's disease: a prospective cohort study. Gastroenterology 125:32-39
22. Sarzi-Puttini P, Ardizzone S, Manzionna G, Atzeni F, Colombo E, Antivalle M, Carrabba M, Bianchi-Porro G (2002) Infliximab-induced lupus in Crohn's disease: a case report. Dig Liver Dis 35:814-817
23. Hanauer SB (1999) Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 13(suppl 4):16-22
24. Shovman O, Gilburd B, Zandman-Goddard G, Yehiely A, Langevitz P, Shoenfeld Y (2005) Multiplexed AtheNA multilyte immunoassay for ANA screening in autoimmune diseases. Autoimmunity 38:105-109